ReviewJournal of ophthalmology2021
Efficacy and Adverse Effects of Atropine for Myopia Control in Children: A Meta-Analysis of Randomised Controlled Trials.
Review in Journal of ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Comparison of the efficacy and safety of different doses of atropine for myopic control in children: a meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Effectiveness of myopia control interventions: A systematic review of 12 randomized control trials published between 2019 and 2021.Frontiers in public health · 2023Pooled it
- Comparison of the influence of 1% and 0.01% atropine on the corneal topography in myopic children.BMC ophthalmology · 2025Trial
- Low-Dose Atropine and Other Interventions for Pediatric Myopia: A Systematic Review and Bayesian Network Meta-analysis of Efficacy and Post-treatment Outcomes.Ophthalmology and therapy · 2026Review
- Microbial and Chemical Stability of Unpreserved Atropine Sulfate 0.01%Life (Basel, Switzerland) · 2025Article
- Effect of Low-Dose Atropine on Choroidal Thickness in Children With Myopia Progression.Cureus · 2025Article
- Comparison of different concentrations atropine in controlling children and adolescent myopia: an umbrella review of systematic reviews and meta-analyses.Frontiers in ophthalmology · 2024Article
- Retardation of myopia by atropine regimes.International journal of ophthalmology · 2024Review
- [Recommendations for progressive myopia in childhood and adolescence. Statement of the DOG, BVA and the Bielschowsky Society for Strabismus Research and Neuroophthalmology : Status June 2022].Die Ophthalmologie · 2023Review
- Efficacy and safety of atropine at different concentrations in prevention of myopia progression in Asian children: a systematic review and Meta-analysis of randomized clinical trials.International journal of ophthalmology · 2023Article
- Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia.Scientific reports · 2022Article
- Effect of 0.01% atropine eyedrops on intraocular pressure in schoolchildren: a randomized clinical trial.International journal of ophthalmology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo explore the rebound effects and safety of atropine on accommodation amplitude in slowing myopia progression.
methodsWe conducted a meta-analysis to testify proper dosage of atropine in children with myopia. We searched in PubMed, EMBASE, Ovid, and the Cochrane Library up to March 30, 2021. We selected randomised controlled trials (RCTs) that evaluated the efficacy of atropine for controlling myopia progression in children. We performed the inverse variance random-effects model to pool the data using mean difference (MD) for continuous variables. Statistical heterogeneity was assessed using the I
resultsSeventeen RCTs involving 2955 participants were included. Myopia progression was significantly less in the atropine group than that of the control group, with MD = 0.38 D per year (95% confidence interval, 0.20 to 0.56). Less axial elongation was shown with MD = -0.19 mm per year (95% CI, -0.25 to -0.12). There was a statistically difference among various doses (
conclusionThe efficacy of atropine is dose dependent, and 0.01% atropine may be the optimal dose in slowing myopia progression in children with no accommodation dysfunction. A rebound effect is more prominent in high-dose atropine in the former cessation after discontinuation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.